HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

Detalles Bibliográficos
Main Authors:	Mafham, M, Preiss, D
Formato:	Journal article
Publicado:	Elsevier 2018

Títulos similares

GLP-1 receptor agonists and cardiovascular outcome trials: An update
por: Eirini Andrikou, et al.
Publicado: (2019-11-01)

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
por: Kristensen, SL, et al.
Publicado: (2019)

An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
por: Mustafa Kılıçkap, et al.
Publicado: (2021-02-01)

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
por: Fatemeh Taktaz, et al.
Publicado: (2024-07-01)

Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
por: Jinjing Wei, et al.
Publicado: (2022-12-01)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
por: María Isabel del Olmo-Garcia, et al.
Publicado: (2018-01-01)

Adverse effects of GLP – 1 Receptor Agonists
por: Anna Kasprzak, et al.
Publicado: (2025-02-01)

GLP-1 Receptor Agonists and Kidney Protection
por: Eulalia Valentina Greco, et al.
Publicado: (2019-05-01)

Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
por: Haran K, et al.
Publicado: (2024-11-01)

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
por: Qiyuan Keith Liu
Publicado: (2024-07-01)

Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist.
por: Qinghua Wang, et al.
Publicado: (2010-09-01)

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
por: Collin Vandemark, et al.
Publicado: (2023-02-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Lisa M Neff, et al.
Publicado: (2010-07-01)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chee&nbsp;W Chia, et al.
Publicado: (2009-05-01)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
por: Daiji Kawanami, et al.
Publicado: (2020-06-01)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
por: Rizvi AA, et al.
Publicado: (2022-04-01)

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
por: Miodrag Janić, et al.
Publicado: (2024-12-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
por: Joanna Wojda, et al.
Publicado: (2025-02-01)

GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
por: Jiani Zhong, et al.
Publicado: (2024-05-01)

GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
por: Sydney S. Wilbon, et al.
Publicado: (2023-12-01)

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
por: Giulia Monti, et al.
Publicado: (2022-06-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010-07-01)

GLP-1 receptor agonist as a modulator of innate immunity
por: Jun Chen, et al.
Publicado: (2022-12-01)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Francis S. Willard, et al.
Publicado: (2020-09-01)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
por: Sara Piccini, et al.
Publicado: (2023-03-01)

GLP-1 receptor agonists—another promising therapy for Alport syndrome?
por: Jan Boeckhaus, et al.
Publicado: (2025-03-01)

Advances in GLP-1 receptor agonists for pain treatment and their future potential
por: Yongtao He, et al.
Publicado: (2025-02-01)

The Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS
por: Aleksandra Jaroń, et al.
Publicado: (2024-08-01)

Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
por: Hong Shurui
Publicado: (2023-01-01)

A potentially serious adverse effect of GLP-1 receptor agonists
por: Jinmiao Lu, et al.
Publicado: (2023-05-01)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Haiyang Du, et al.
Publicado: (2022-11-01)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
por: Jinmi Lee, et al.
Publicado: (2012-08-01)

GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
por: Aurélie Pahud de Mortanges, et al.
Publicado: (2022-03-01)

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
por: Karen Schneck, et al.
Publicado: (2024-03-01)

The benefits of GLP1 receptors in cardiovascular diseases
por: Lamija Ferhatbegović, et al.
Publicado: (2023-12-01)

GLP-1 agonists in treatment of obesity
por: Władysław Orłowski, et al.
Publicado: (2023-01-01)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
por: Amisha Wallia, et al.
Publicado: (2023-05-01)

GLP-1 receptor agonists: a review of head-to-head clinical studies
por: Jennifer M. Trujillo, et al.
Publicado: (2015-02-01)

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
por: Enrico Longato, et al.
Publicado: (2020-06-01)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
por: W. Timothy Garvey, et al.
Publicado: (2024-06-01)